Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 1
A Phase 1B Double Blinded Randomized Trial Evaluating Safety, Tolerability, and Immune Response of OSU-2131 a BZLF1 Peptide Vaccine With Stimulon™ QS-21 Solution Adjuvant in Healthy Volunteers and Patients Awaiting Solid Organ Transplantation
This phase 1B trial tests the safety, side effects and best dose of rh-Hsc70- BZLF1 peptide complex (OSU-2131) with Stimulon (Trademark) QS-21 and evaluates ho…
Chronic Kidney Disease, Stage 4Chronic Kidney Disease, Stage 5EBV-Related Lymphoproliferative Disorder+2 more
Estimated
~$10 – $6,250
Ohio State University Comprehensive Cancer CenterNCT06741072
Phase 2
Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
This phase II trial tests how well tafasitamab and rituximab work for front-line treatment of patients with post-transplant lymphoproliferative disorder. Post-…
Monomorphic B-Cell Post-Transplant Lymphoproliferative DisorderPolymorphic Post-Transplant Lymphoproliferative Disorder
Estimated
~$10 – $7,500
Timothy VoorheesNCT05786040
Phase 1
A Phase 1/2 Study of Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)
The purpose of phase I of this clinical trial is to learn the recommended dose of the drugs loncastuximab tesirine and rituximab in participants with post-tran…
Post-transplant Lymphoproliferative Disorder
Estimated
~$10 – $6,250
University of UtahNCT07573436
Phase 1
Phase Ib Study to Assess the Efficacy and Safety of Epcoritamab in Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder
This phase Ib trial tests the safety and effectiveness of epcoritamab in treating patients with post-transplant lymphoproliferative disorder (PTLD) that has co…
Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative DisorderEBV-Related Post-Transplant Lymphoproliferative DisorderRecurrent Monomorphic Post-Transplant Lymphoproliferative Disorder+3 more
Estimated
~$10 – $7,500
Timothy VoorheesNCT06672705